detection du cancer de la prostate place de ’ biopsies ciblees
TRANSCRIPT
![Page 1: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/1.jpg)
DETECTION DU CANCER DE LA PROSTATE
PLACE DE L’IRM
_____
BIOPSIES CIBLEESDaniel PORTALEZ
Philips Healthcare
SFR Languedoc Roussillon
![Page 2: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/2.jpg)
Le Cancer de la Prostate
Probl�me de Sant� Publique
2010 Nouveaux cas D�c�s
USA* 217 730 32 050
France** 71 600 8 800
Sources: * Cancer Statistics, 2010 Ahmedin Jemal** INCA
Cancer le plus fr�quent chez l'homme, avant le cancer du poumon (26.900 cas) et le cancer colorectal (21.100 cas). En termes de mortalit�, le cancer de la prostate (8.800 d�c�s) se situe apr�s le cancer du poumon (21.100 d�c�s) et le cancer colorectal (9.200 d�c�s).
SFR Languedoc Roussillon
![Page 3: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/3.jpg)
SFR Languedoc Roussillon
![Page 4: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/4.jpg)
INVS 2008
SFR Languedoc Roussillon
![Page 5: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/5.jpg)
Le Cancer de la Prostate
Soul�ve des Controverses
Alors que nous ne savons pas combien seraient morts de leur cancer
Frankel S. Screening for prostate cancer. Lancet. 2003;361:1122-8. )
1 Million d’hommes >50 ans
110 000 PSA �lev�s
90 000 Biopsies
20 000 Cancers
10 000 Op�r�s 10 D�c�d�s
300 Incontinents3000 Impuissants
SFR Languedoc Roussillon
![Page 6: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/6.jpg)
AupÄrin A, Laplanche A, Hill C, DÄpistage du Cancer de la Prostate dans la Population gÄnÄrale, Presse Med 2007.
SFR Languedoc Roussillon
![Page 7: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/7.jpg)
SFR Languedoc Roussillon
![Page 8: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/8.jpg)
Le Cancer de la Prostate
Soul�ve des Controverses
Et si on fait quelque chose on nous le reprochera aussi
Si on ne fait rien on nous le reprochera
SFR Languedoc Roussillon
![Page 9: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/9.jpg)
Etude ERSPC (European Randomized study of Screening for Prostate Cancer)
La plus importante �tude randomis�e sur le d�pistage du cancer de la prostate
162 243 hommes de 55 � 69 ans : diminution de 20 % du risque de d�c�der d'un cancer de la prostate dans le bras b�n�ficiant d'un d�pistage r�gulier par rapport � une population contr�le sans d�pistage organis�. Mais �tait associ� � un risque plus �lev� de sur-diagnostic
N ENGL J MED 2009; 360:1320-1328 March 26, 2009
SFR Languedoc Roussillon
![Page 10: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/10.jpg)
EVITER LE SURTRAITEMENT
SFR Languedoc Roussillon
![Page 11: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/11.jpg)
D’Amico, JAMA 1998
Risque faible <15%PSA≤10ng/mlGleason ≤6
Risque interm�diairePSA 10-20ng/mlGleason ≤7
Risque �lev� >65%PSA≥20ng/mlGleason>7
1009080706050403020100
4022252132
3321407031
210664527
134312720
76121810
41274
0 1 2 3 4 5
10090807060
5040
3020
100
2303002310
1582181413
473800
261200
11000
0 1 2 3 4
10090807060
5040
3020
100
2432323815
1121433110
1167796
723244
381023
36401
1021034
50 1 2 3 4 5
Temps ( annÄes) Temps ( annÄes) Temps ( annÄes)
PSA S
urvi
e %
Prostatectomie radicale Implant et traitement hormonal n�oadjuvant
Radioth�rapie externe Implant
RISQUE DE RECHUTE =15 � 67% � 5 ans
CANDIDATS A SURVEILLANCE ACTIVE
TRAITEMENT FOCAL
SFR Languedoc Roussillon
![Page 12: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/12.jpg)
LES MOYENS DE DETECTIONSFR Languedoc Roussillon
![Page 13: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/13.jpg)
DOSAGE DU PSA
• Test acceptable• Sensible (Se= 85% seuil =4 ng/ml)• Peu sp�cifique (pour les cancers
d�butants)• VPP 25 � 30 % (seuil 4 ng/ml)
SFR Languedoc Roussillon
![Page 14: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/14.jpg)
LES MOYENS DE DIAGNOSTICSFR Languedoc Roussillon
![Page 15: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/15.jpg)
BIOPSIES SYSTEMATISEES / ECHO 2D
Taux d’�chec de 10 � 38% (1)
Cancer de l’apex, lat�ral, ant�rieur : taux d’echec 73% (1)
1. Patel AR Urology 2004
2. Presti J Jr Nat Clin Pract Urol 2008
Re-Biopsies: taux de d�tection de 34%, 25%, 24%, 21%
pour 1�re, 2�me, 3�me, 4�me (2)
SFR Languedoc Roussillon
![Page 16: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/16.jpg)
PROBLEMATIQUE
NECESSITE DE DETECTION PRECOCE
EVITER LE SURTRAITEMENT
INSUFFISANCE DU PSA ET DES BIOPSIES
IRM
BIOPSIES CIBLEES
CHOIX THERAPEUTIQUE
SFR Languedoc Roussillon
![Page 17: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/17.jpg)
1. T2w - T1w
2. DIFFUSION
3. PERFUSION
4. SPECTROSCOPIE
IRM DE DETECTION MULTIMODALITES
Analyse m�tabolique : [citrate et choline]
Analyse vasculaire : cin�tique du contraste
Analyse du mouvement des mol�cules H2O
Analyse morphologique
SFR Languedoc Roussillon
![Page 18: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/18.jpg)
SFR Languedoc Roussillon
![Page 19: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/19.jpg)
SFR Languedoc Roussillon
![Page 20: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/20.jpg)
SFR Languedoc Roussillon
![Page 21: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/21.jpg)
SFR Languedoc Roussillon
![Page 22: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/22.jpg)
SFR Languedoc Roussillon
![Page 23: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/23.jpg)
SFR Languedoc Roussillon
![Page 24: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/24.jpg)
Mars 2010
Mai 2011
SFR Languedoc Roussillon
![Page 25: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/25.jpg)
SFR Languedoc Roussillon
![Page 26: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/26.jpg)
SFR Languedoc Roussillon
![Page 27: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/27.jpg)
b 600 b 2000
SFR Languedoc Roussillon
![Page 28: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/28.jpg)
SFR Languedoc Roussillon
![Page 29: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/29.jpg)
SFR Languedoc Roussillon
![Page 30: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/30.jpg)
SFR Languedoc Roussillon
![Page 31: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/31.jpg)
SFR Languedoc Roussillon
![Page 32: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/32.jpg)
IRM - PerfusionIRM - Perfusion
DETECTION Sens. Sp�c.1.5T Jager GJ Rgy 1997 73% 81%
3T Kim CK JCAT 2006 73% 77%
Utilis�e en DETECTION mais insuffisanteUtilis�e en DETECTION mais insuffisante
DETECTION CANCERS DE LA ZT
Sens. Sp�c.
T2 seul 50 % 51 %
Gadolinium +T2 60 % 72 %
Li H. AJR 2006
SFR Languedoc Roussillon
![Page 33: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/33.jpg)
DETECTION Sens. Sp�c.
Wefer Rgy 2000 56% 82%
Jung Rgy 2004 64% 93%
Yuen Rgy 2004 57% 82%
Prando Rgy 2005 71% 84%
IRM - Spectroscopique IRM - Spectroscopique
Utilis�e en DETECTION mais insuffisanteUtilis�e en DETECTION mais insuffisante
SFR Languedoc Roussillon
![Page 34: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/34.jpg)
Sens Sp�c
T2 54% 84%
T2+DWI 81% 84%
Haider, M. A. et al. Am. J. Roentgenol. 2007
D�tection des cancers de la ZP > 4mm Gleason>VI
IRM Diffusion IRM Diffusion SFR Languedoc Roussillon
![Page 35: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/35.jpg)
Probability(%) in PZ T2-MRI DCE-MRI MRSI DWI
Negative Positive Negative Positive Negative Positive
T2-MRI Negative 6.2 5.8 14.9 4.1 11.7 5.2 32.9
Positive 29.4 22.4 44.7 17.8 39.7 16.2 63.4
IRM DE DETECTION MULTIPARAMETRIQUE AVANT RE-BIOPSIES / TRUS
68 patients- 28 cancers ( 41,2%) – 41 cancers / 408 segments ZP
D. Portalez, B. Malavaud Eur. Rgy 2010
SFR Languedoc Roussillon
![Page 36: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/36.jpg)
Prostate Cancer: Comparison of Tumor Visibility on Trace Diffusion-Weighted Images and the Apparent Diffusion Coefficient Map
AB. Rosenkrantz AJR:196, January 2011
% de foyers tumoraux dans la ZP identifi�s � la prostatectomie radicale qui �taient visibles en IRM
IRM DiffusionSFR Languedoc Roussillon
![Page 37: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/37.jpg)
Class of Voxel ADC x 10–3 mm2/s
Peripheral zone 1.51 � 0.27 (1.05–2.05)
Central gland 1.31 � 0.20 (0.82–1.78)
Mixed voxels 1.34 � 0.24 (0.86–1.86)
Tumor 30% of voxel 1.19 � 0.24 (0.71–1.93)
Tumor 70% of voxel 1.03 � 0.18 (0.74–1.38)
Reinsberg AJR 2007
FAUT-IL UTILISER LES VALEURS D’ADC ?
IRM DiffusionSFR Languedoc Roussillon
![Page 38: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/38.jpg)
IRM Diffusion
Turkbey B et al. Radiology 2011;258:488-495
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3T-MR images ?
SFR Languedoc Roussillon
![Page 39: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/39.jpg)
IRM Diffusion
Turkbey B et al. Radiology 2011;258:488-495
a b
SFR Languedoc Roussillon
![Page 40: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/40.jpg)
Et si la longueur des doigts �tait un indice de risque du cancer de la prostate
Les hommes dont l'index est plus long que l'annulaire ont un risque de cancer de la prostate inf�rieur de plus de 30 % � ceux qui sont dans la situation inverse.
Cancers : des chiens renifleurs pour traquer la sarcosine
INDICATIONS DE l’IRM EN DETECTION DU CANCER DE LA PROSTATE
SFR Languedoc Roussillon
![Page 41: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/41.jpg)
IRM Multimodalit�s: Indications
1.Biopsies n�gatives : suspicion de cancer
Progression du PSA
PCA3 > 30
ATYP Atypic glands suspicious for cancer
Atrophie glandulaire
PIN de haut grade
2. Biopsies positives: Surveillance active
SFR Languedoc Roussillon
![Page 42: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/42.jpg)
Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat BiopsyA. Haese Eur Urol. 2008
PCA3
BIOPSIES NEGATIVES: suspicion de cancerSFR Languedoc Roussillon
![Page 43: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/43.jpg)
T1c-T2a cliniquePSA < 10 ng/mlGleason score ≤ 6≤ 2 biopsies positives≤ 50% cancer sur chaque biopsie
GUIDELINES ON PROSTATE CANCERA. Heidenreich Eur Urol 2011
Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance. Porten SP J Clin Oncol. 2011 May 31.
Surveillance active 1988-2009 chez 377 hommes
Augmentation du grade de Gleason dans 34%
dont 81% � la 2�me s�rie de biopsies
BIOPSIES POSITIVES: Surveillance activeSFR Languedoc Roussillon
![Page 44: DETECTION DU CANCER DE LA PROSTATE PLACE DE ’ BIOPSIES CIBLEES](https://reader035.vdocuments.us/reader035/viewer/2022062405/62aba80a9ab552424563b18d/html5/thumbnails/44.jpg)
2011: L’IRM MULTIPARAMETRIQUE EST UNE TECHNIQUE FIABLE POUR :
- DETECTER LE CANCER DE LA PROSTATE
- LE LOCALISER EN VUE DE BIOPSIES CIBLEES
SFR Languedoc Roussillon